SCHEMBL4351097

SCHEMBL4351097

Cc1cccc(CNc2cc(F)c(O)c(F)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.45
MAPT P10636 4/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HDAC4 P56524 1/20 0.42
MEF2D Q14814 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
FFAR1 O14842 2/20 0.42
FFAR4 Q5NUL3 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MMP13 P45452 1/20 0.40
OPRM1 P35372 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4341648 0.85 MAPT (0.49) GFERMAPTHPGDHTTCYP1A2
SCHEMBL8447034 0.82 NOS2 (0.47) GFERMAPTHPGDHTTCYP1A2
SCHEMBL4347062 0.81 P2RX7 (0.48) GFERMAPTHPGDHTTCYP1A2
SCHEMBL4345895 0.80 BRD4 (0.43) GFERMAPTHPGDHTTCYP1A2
SCHEMBL4352193 0.79 FFAR1 (0.55) MAPTCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL21241028 0.78 MAPT (0.64) GFERMAPTHPGDHTTCYP1A2
SCHEMBL4347397 0.78 BRD4 (0.41) GFERMAPTHPGDCYP1A2CYP3A4
SCHEMBL4358595 0.77 FFAR1 (0.59) MAPTFFAR1FFAR4MEN1KMT2A
SCHEMBL11831264 0.76 HTT (0.63) GFERMAPTHPGDHTTCYP1A2
SCHEMBL25547404 0.76 HTT (0.69) GFERMAPTHPGDHTTFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 GFER 2138/4885MAPT 4439/4885HPGD 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.